DINAMO phase III clinical trial met primary endpoint

The DINAMO phase III clinical trial met its primary endpoint by demonstrating a statistically significant reduction in HbA1c with Jardiance compared with placebo for children and adolescents aged 10-17 years living with type 2 diabetes. When Jardiance was added to other baseline treatments HbA1c was reduced by 0.84% compared with placebo at week 26. The results were presented at the International Diabetes Federation, or IDF, World Diabetes congress 2022, Boehringer Ingelheim and Eli Lilly and Company announced. The DINAMO,DIabetes study of liNAgliptin and eMpagliflozin in children and adOlescents, trial included youth aged 10-17 years with type 2 diabetes and HbA1c greater than or equal to6.5% and less than or equal to10.5%. Participants were randomly assigned treatment with Jardiance, Tradjenta or placebo once daily. All participants were treated with diet and exercise plus, when appropriate, metformin and/or insulin.